rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['rucaparib', 'brca', 'crpc', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'triton3']
exciting results from triton3 at asco #gu23! interim os suggests an advantage for rucaparib compared to physician s choice in pts with mcrpc and brca alterations. rucaparib also significantly improved rpfs and maintained safety. share your thoughts on this finding below! 